Hagihara Y., Suetsugu T., Uto H., Kozono T., Masada Y., Satozono Y., Shinmura M., Koreeda Y., Mizuno K., Inoue H. . Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E muta2023 · 記述言語： 日本語 出版者・発行元： Respiratory Investigation Osimertinib has demonstrated efficacy as the first- and second-line treatment for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. However, EGFR-mutant NSCLC cells often acquire resistance to osimertinib. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation (BRAF V600E) was detected in a re-biopsy (LC-SCRUM-TRY testing) of a patient with advanced lung adenocarcinoma who was resistant to osimertinib treatment. Currently, the patient is receiving dabrafenib/trametinib combination therapy and is under observation; a slight shrinking effect of cancer has been observed. DOI： 10.1016/j.resinv.2023.09.006 Scopus PubMed
